- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
Camlin Fine Sciences (CFS) reported Q1FY27 revenues of ₹519.9 Cr (up 28% YoY) but low 4% margins, primarily due to high raw material costs and a one-quarter lag in price pass-through. Specialty Ingredients saw 6.35% EBITDA, while Aroma had negative EBITDA from cautious Ethyl Vanillin ramp-up and low capacity utilization....
The audio recording of Camlin Fine Sciences Limited's conference call on the un-audited financial results (consolidated and standalone) for the quarter ended June 30, 2026, is now available on the company's website. Management was represented by Mr. Ashish Dandekar, Mr. Nirmal Momaya, and Mr. Santosh Parab.
Camlin Fine Sciences (CFS) achieved its highest-ever quarterly revenue in Q1FY27 at ₹519.9 Cr, marking a 27.5% YoY jump. Despite this, consolidated EBITDA stood at ₹17.6 Cr (3.4% margin), and the company posted a Net Loss of ₹31.8 Cr. Gross margins were impacted by higher raw material prices and limited...